Drugs / LT-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06436976 | Mar → Dec 2024 | colorectal cancer, malignant pancreatic neoplasm | Chungnam National University Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-03-20 | Novartis Pharmaceuticals | Results Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset novartis.com ↗
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking |
| 2021-03-15 | Novartis Pharmaceuticals | Results New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment novartis.com ↗
Eleven new milestones were achieved by four patients (17 percent), including sitting without support by all four patients (three were not receiving concomitant disease-modifying SMA therapy). |
All press releases naming this drug 2 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LT-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06436976 ↗ |